We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Scientists Develop Implantable Telescope

By HospiMedica staff writers
Posted on 29 Aug 2007
Researchers are exploring the use of an implantable miniature telescope for use in end-stage age-related macular degeneration (AMD).

The Implantable Miniature Telescope (IMT) is designed to be a permanent solution for moderate to profound vision loss due to advanced, end-stage forms of AMD that have no current surgical or medical treatment options. More...
Smaller than a pea, the telescope prosthetic device is implanted in one eye in an outpatient surgical procedure. In the implanted eye, the device renders enlarged central vision images over a wide area of the retina to improve central vision, while the non-operated eye provides peripheral vision for mobility and orientation.

A prospective, multi-center phase II/III trial to evaluate the safety and efficacy of the IMT in individuals with moderate to profound bilateral central vision impairment enrolled over 200 patients at 28 leading medical universities and ophthalmic centers across the United States. The IMT was invented by VisionCare Ophthalmic Technologies (Saratoga, CA, USA). VisionCare has filed a pre-market approval (PMA) application with the U.S. Food and Drug Administration (FDA) for the telescope prosthesis. The surgical procedure for implantation of the IMT was developed at the Massachusetts Eye and Ear Infirmary (MEEI; Boston, USA; www.meei.harvard.edu), and was described in the August 2007 issue of the Archives of Ophthalmology.

"What the telescope does is by enlarging the image the patient image is looking at, it allows them to see around these scotoma, or holes in their vision,” said lead author Kathryn Colby, M.D., Ph.D., director of the Joint Clinical Research Center (JCRC) at the MEEI.

Age-related macular degeneration is a group of conditions that include deterioration of the macula, resulting in loss of sharp central vision. Two general types: dry, which is more common, and wet, in which abnormal new blood vessels grow under the retina and leak fluid and blood (neovascularization), further disturbing macular function. AMD is the most common cause of decreased vision after age 60.


Related Links:
Massachusetts Eye and Ear Infirmary
VisionCare Ophthalmic Technologies

Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
Gold Member
Electrode Solution and Skin Prep
Signaspray
Premium Air-Mattress
MA-51
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.